OncoCyte Corp (OCX) Stock Rating Lowered by Zacks Investment Research

oncocyte-corp-ocx-stock-rating-lowered-by-zacks-investment-research.png

OncoCyte Corp (NYSE:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Several other equities analysts have also weighed in on the stock. Canaccord Genuity reissued a “buy” rating on shares of OncoCyte Corp in a research report on Wednesday, June 15th. Benchmark Co. raised their price target on shares of OncoCyte Corp from $7.50 to $8.00 and gave the stock a “speculative buy” rating in a research report on Tuesday, June 7th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/oncocyte-corp-ocx-stock-rating-lowered-by-zacks-investment-research.html

OncoCyte Corp (NYSE:OCX) opened at 3.65 on Friday. The firm has a 50 day moving average of $3.96 and a 200-day moving average of $4.42. The company’s market capitalization is $92.82 million. OncoCyte Corp has a 52 week low of $2.45 and a 52 week high of $10.24.
OncoCyte Corp (NYSE:OCX) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. On average, analysts forecast that OncoCyte Corp will post ($0.45) earnings per share for the current year.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Receive News & Ratings for OncoCyte Corp Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OncoCyte Corp and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "OncoCyte Corp (OCX) Stock Rating Lowered by Zacks Investment Research"

Leave a comment

Your email address will not be published.


*